KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.00 USD
-0.15 (-2.44%)
Updated Jun 13, 2024 03:50 PM ET
After-Market: $6.02 +0.02 (0.33%) 5:18 PM ET
4-Sell of 5 4
F Value B Growth B Momentum D VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 161 - 180 ( 365 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; EYSUVIS Launch by YE; Well-Positioned for Long-Term Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financial Results; EYSUVIS Launch Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves EYSUVIS for Dry Eye Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Rapid Approval For Rapid Relief: EYSUVIS Now Eyes Near- Term Launch by YE:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Outlines Opportunity in Dry Eye Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS- Takes Center Stage Ahead of its October 30th PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L